The Role of and Gene Polymorphisms in Prolactinoma: Gene Polymorphisms May Be Associated with Tumor Shrinkage

Overview

Journal In Vivo

Specialty Oncology

Date 2017 Apr 26

PMID 28438863

Citations 1

Authors

Seda Turgut

Muzaffer Ilhan

Saime Turan

Ozcan Karaman

Ilhan Yaylim

Ozlem Kucukhuseyin

Ertugrul Tasan

Affiliations

Soon will be listed here.

Abstract

Aim: Prolactinomas are thought to arise from clonal expansion of a single mutated cell which is subjected to growth stimuli of several permissive factors, although the pathogenetic mechanisms underlying tumorigenesis remain unclear. The present study aimed to investigate the role of p16 (540C→G and 580C→T) and mouse double minute 2 (MDM2) (SNP309T→G) gene polymorphisms in tumorigenesis and characteristics of prolactinoma.

Patients And Methods: A total of 74 patients with prolactinoma and 100 age- and gender-matched healthy individuals were enrolled in the study. Serum prolactin levels were measured by enzyme-linked immunosorbent assay (ELISA). p16 and MDM2 polymorphisms were determined by polymerase chain reaction-restriction fragment polymorphism and agarose gel electrophoresis.

Results: p16 540C→G genotype distribution was found to be: CC: 66.2%, CG: 28.4%, GG: 5.4%; p16 580C→T genotype distribution was found to be: CC: 82.4%, CT: 17.6%, TT: 0% and MDM2 genotype distribution was found to be: TT: 31.1%, TG: 47.3%, GG: 21.6% in patients with prolactinoma. Tumor diameter before treatment was correlated with prolactin levels before treatment and percentage of prolactin decrease with treatment (r=0.719, p<0.001, p=0.034 r=0.256, respectively). The number of patients with tumor size decrease of more than 50% in those with homozygous genotype (TT+GG) of MDM2 SNP309T→G was significantly higher than in heterozygous genotype (TG) carriers (odds ratio(OR)=0.18, 95% confidence interval(CI)=0.06-0.58; p=0.003).

Conclusion: This study showed that p16 and MDM2 polymorphisms do not play a decisive role in tumorigenesis, but some genotypes of these polymorphisms might be associated with follow-up characteristics of prolactinoma.

Citing Articles

A research on the protein expression of p53, p16, and MDM2 in endometriosis.

Sang L, Fang Q, Zhao X Medicine (Baltimore). 2019; 98(14):e14776.

PMID: 30946310 PMC: 6456087. DOI: 10.1097/MD.0000000000014776.

References

Aflorei E, Korbonits M . Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol. 2014; 117(3):379-94. DOI: 10.1007/s11060-013-1354-5. View

Melmed S . Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest. 2003; 112(11):1603-18. PMC: 281651. DOI: 10.1172/JCI20401. View

Oliner J, Kinzler K, Meltzer P, GEORGE D, Vogelstein B . Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992; 358(6381):80-3. DOI: 10.1038/358080a0. View

Fernandez A, Karavitaki N, Wass J . Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2009; 72(3):377-82. DOI: 10.1111/j.1365-2265.2009.03667.x. View

Zhou Y, Zhang X, Klibanski A . Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Mol Cell Endocrinol. 2013; 386(1-2):16-33. PMC: 3943596. DOI: 10.1016/j.mce.2013.09.006. View

Dworakowska D, Grossman A . The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009; 23(5):525-41. DOI: 10.1016/j.beem.2009.05.004. View

Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y . MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007; 13(14):4123-9. DOI: 10.1158/1078-0432.CCR-07-0609. View

Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T . Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol. 1996; 55(10):1026-31. View

Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R . Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol (Oxf). 2001; 54(3):317-25. DOI: 10.1046/j.1365-2265.2001.01195.x. View

10.

Tuna G, Kucukhuseyin O, Arikan S, Kaytan Saglam E, Guler E, Cacina C . Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?. DNA Cell Biol. 2013; 32(7):400-8. DOI: 10.1089/dna.2012.1933. View

11.

Boersma B, Howe T, Goodman J, Yfantis H, Lee D, Chanock S . Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst. 2006; 98(13):911-9. DOI: 10.1093/jnci/djj245. View

12.

Levy A, Hall L, Yeudall W, Lightman S . p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol (Oxf). 1994; 41(6):809-14. DOI: 10.1111/j.1365-2265.1994.tb02797.x. View

13.

Knappskog S, Lonning P . MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget. 2011; 2(3):251-8. PMC: 3260817. DOI: 10.18632/oncotarget.243. View

14.

Hartwell L, Kastan M . Cell cycle control and cancer. Science. 1994; 266(5192):1821-8. DOI: 10.1126/science.7997877. View

15.

Seemann N, Kuhn D, Wrocklage C, Keyvani K, Hackl W, Buchfelder M . CDKN2A/p16 inactivation is related to pituitary adenoma type and size. J Pathol. 2001; 193(4):491-7. DOI: 10.1002/path.833. View

16.

Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

17.

FREEDMAN D, Levine A . Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1999; 59(1):1-7. View

18.

Lois A, Cooper L, Geng Y, Nobori T, Carson D . Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation. Cancer Res. 1995; 55(18):4010-3. View

19.

Colao A . Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009; 23(5):575-96. DOI: 10.1016/j.beem.2009.05.003. View

20.

Heaney A, Melmed S . New pituitary oncogenes. Endocr Relat Cancer. 2000; 7(1):3-15. DOI: 10.1677/erc.0.0070003. View